Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca ( (GB:AZN) ) has provided an announcement.
AstraZeneca has announced that as of September 30, 2025, its issued share capital with voting rights consists of 1,550,701,945 ordinary shares, with no shares held in Treasury. This information is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
AstraZeneca’s strong financial performance and positive earnings call are the primary drivers of its overall score. However, bearish technical indicators and a relatively high valuation weigh down the score. The company’s robust pipeline and strategic initiatives provide a positive outlook despite some market challenges.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, UK. It focuses on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in over 125 countries and are used by millions of patients worldwide.
Average Trading Volume: 2,233,095
Technical Sentiment Signal: Strong Buy
Current Market Cap: £171.9B
For detailed information about AZN stock, go to TipRanks’ Stock Analysis page.